Lilly defends blockbuster Alimta with unusual ammo

(Reuters) – Eli Lilly and Co, now facing one of the worst patent cliffs in its history, could find $15 billion in sorely needed relief if it beats the odds and wins a closely watched patent battle with generic drugmaker Teva Pharmaceutical Industries .

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.